| Hewes D Agnew, MD | |
|
1020 N 27th St, Billings, MT 59101-0760 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Hewes D Agnew |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery (cardiothoracic Vascular Surgery) |
| Location | 1020 N 27th St, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285703330 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 3593 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Hewes D Agnew, MD Po Box 37000, Billings, MT 59107-7000 Ph: (406) 238-2500 | Hewes D Agnew, MD 1020 N 27th St, Billings, MT 59101-0760 Ph: (406) 238-2500 |
News Archive
Non-alcoholic fatty liver disease, the accumulation of fat in the liver of people who drink little or no alcohol, affects 1 in 3 Americans. NAFLD is a significant risk factor for Type 2 diabetes, insulin resistance, and hepatic carcinoma, and incidence of the disease is increasing with the growing obesity epidemic in the United States.
The consistency and quality of the long-term clinical results for the Endeavor® drug-eluting stent (DES) from Medtronic, Inc., continue to distinguish it as a treatment for coronary artery disease, according to newly released data.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the "bystander effect" in treating metastatic melanoma. Dr. Agarwala's presentation, entitled "Chemoablation in Melanoma: An Update," was given in the session entitled "Unique Approaches to Melanoma Therapy."
When it comes to the deadly skin cancer melanoma, studying functional tissue rather than cell lines may better provide insight into the disease's development, according to new research from a Howard Hughes Medical Institute predoctoral fellow at Stanford University School of Medicine.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
› Verified 5 days ago
Dr. James John Morris, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 2900 12th Ave N, Suite 400e, Billings, MT 59101 Phone: 406-238-6820 Fax: 406-238-6838 | |
Dr. Alexander Kraev, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Eric Blake Howell, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |